Objective Although neurodevelopmental outcomes for management of patent ductus arteriosus with intravenous indomethacin and ibuprofen are known, there has been lack of data on long term effects of oral ibuprofen in the literature.
Method To assess the neurodevelopmental outcomes at 18–24 months’ corrected age, we conducted a prospective follow-up study of 99 infants with birth weight ≤1500 g and gestational age ≤32 weeks who recieved either oral or intravenous ibuprofen for patent ductus arteriosus.1) Moderate/severe cerebral palsy with functional deficits, 2) bilateral hearing loss and blindness in either eye, and 3) mental developmental index score or psychomotor index score less than 70 were defined as abnormal neurologic, neurosensory and cognitive outcomes, respectively.
Results At 18–24 months’ corrected age, neurodevelopmental outcomes of 30 (60.0%) among 50 subjects who received oral ibuprofen were compared with 27 (55.1%) of 49 who received intravenous ibuprofen by certified and experienced examiners who were blinded to the groups. The results revealed that long term outcomes did not significantly differ among treatment regimes.
Conclusion Preterm infants who were treated with oral ibuprofen for patent ductus arteriosus have similar neurological, neurosensory and cognitive outcomes with patients who recieved intravenous ibuprofen at 18–24 months’ corrected age.